ProCE Banner Activity

Phase III HOPE-B: Etranacogene Dezaparvovec Gene Therapy in Adults With Severe or Moderately Severe Hemophilia B

Slideset Download
Conference Coverage
Initial results from HOPE-B, the largest phase III study of gene therapy for hemophilia B to date, show etranacogene dezaparvovec yields clinically meaningful levels of factor IX activity within 6 months.

Released: December 10, 2020

Expiration: December 09, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology